$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the price trend of besotivan in 2025 to help you use the drug rationally!
2026-02-01 22:25:32
Check Details
What are the side effects of tucatinib? Common adverse reactions and countermeasures
2026-02-01 22:25:32
Check Details
How effective is Apelvis in treating breast cancer? Applicable population and clinical research data analysis
2026-02-01 22:25:32
Check Details
What is selumetinib? Analysis of main ingredients, indications and treatment mechanisms
2026-02-01 22:25:32
Check Details
Cabozantinib: role and indications of a multi-target tyrosine kinase inhibitor
2026-02-01 22:25:32
Check Details
Important information and correct usage of enzalutamide (enzalutamide) package insert
2026-02-01 22:25:32
Check Details
How much does a box of sorafenib cost? Are prices different in different regions and pharmacies?
2026-02-01 22:25:32
Check Details
What key information is included in the package insert for fostatinib? How to use this medicine correctly?
2026-02-01 22:25:32
Check Details
Is pitobrutinib available in China? What is the release date and related approval information for this drug?
2026-02-01 22:25:32
Check Details
Is Lenvatinib (Lenvatinib) a targeted drug or an immune drug? What type of treatment does it belong to?
2026-02-01 22:25:32
Check Details
What are the indications for Fezonatant? What diseases or conditions is it used to treat?
2026-02-01 22:25:32
Check Details
How much does Besudil cost in China?
2026-02-01 22:25:32
Check Details
1
2
...
1417
1418
1419
1420
1421
1422
1423
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
4
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Revumenib: Key Considerations Before and During Treatment
7
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
8
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
9
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
10
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
11
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
12
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits